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1424Objective: The mortality of pneumonectomy after chemotherapy or chemoradiotherapy for locally advanced
non–small-cell lung cancer is reported to be as high as 26%. We retrospectively reviewed the medical records
of patients undergoing these procedures in 2 specialized thoracic centers to determine the outcome.
Methods: Retrospective analyses were performed of all patients who underwent pneumonectomy after neoadju-
vant chemotherapy or chemoradiotherapy for locally advanced non–small-cell lung cancer from 1998 to 2007.
Presurgical treatment consisted of 3-4 platin-based doublets alone in 20% of patients or combined with radiother-
apy (45Gy) to the tumor and mediastinum in 80% of patients.
Results: Of 827 patients who underwent neoadjuvant therapy, 176 pneumonectomies were performed, including
138 (78%) extended resections. Post-induction pathologic stages were 0 in 36 patients (21%), I in 33 patients
(19%), II in 38 patients (21%), III in 57 patients (32%), and IV in 12 patients (7%). Three patients died of pul-
monary embolism, 2 patients of respiratory failure, and 1 patient of cardiac failure, resulting in a 90 postoperative
day mortality rate of 3%; 23 major complications occurred in 22 patients (13%). For the overall population,
3-year survival was 43% and 5-year survival was 38%.
Conclusion: Pneumonectomy after neoadjuvant therapy for non–small-cell lung cancer can be performed with
a perioperative mortality rate of 3%. Thus, the need of a pneumonectomy for complete resection alone should
not be a reason to exclude patients from a potentially curative procedure if done in an experienced center. The
5-year survival of 38%, which can be achieved, justifies extended surgery within a multimodality concept for se-
lected patients with locally advanced non–small-cell lung cancer. (J Thorac Cardiovasc Surg 2010;139:1424-30)Earn CME credits at
http://cme.ctsnetjournals.org
Despite the fact that more than one third of all patients with
non–small-cell lung cancer (NSCLC) present with stage III
disease at the time of diagnosis, there remain controversies
about treatment recommendations for these patients. Many
centers treat patients with locally advanced disease with pal-
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The Journal of Thoracic and Cardiovascular Surcal resections, especially if a pneumonectomy would be
necessary for complete resection.
Since the 1990s, neoadjuvant therapy, in particular preoper-
ative chemotherapy, has been increasingly used for stage III
NSCLC to downstage tumors, to render them completely re-
sectable, and to possibly eradicate lymph node metastasis in
the mediastinum.1 Several smaller randomized studies have
reported survival benefits from neoadjuvant chemotherapy
followed by surgery compared with surgery alone.1,2 To
further improve local control of the tumor and to clear the
mediastinum from lymph node metastasis, chemotherapy has
also been combined with radiotherapy of the tumor and
mediastinum. However, this was associated with a higher risk
of intraoperative and postoperative complications, and the
best way to combine chemotherapy and radiotherapy has not
been determined.3,4 Some series have reported an increase of
morbidity from 20% to 60% and an exceedingly high
perioperative mortality of up to 26% when pneumonectomy
was performed, especially on the right side.5-7 This led to the
conclusion by some authors that pneumonectomy after
neoadjuvant chemotherapy or chemoradiotherapy should be
avoided in all cases. However, such dismal outcomes are
not observed by all, and some smaller studies reported even
no perioperative deaths in patients who underwent
pneumonectomy after chemoradiotherapy.4,5gery c June 2010
TABLE 1. Repartition of preinduction clinical stages
Total cTNM n
IIB 8 T2N1 8
IIIA 72 T3N1 1
T1-3N2 71
IIIB 94 T4N0-2 67
T4N3 13
T1-3N3 14
IV 2 M1 (BRA) 2
Abbreviations and Acronyms
ARDS ¼ acute respiratory distress syndrome
BPF ¼ bronchopleural fistula
CT ¼ computed tomography
HR ¼ hazard ratio
NSCLC ¼ non–small-cell lung cancer
PET ¼ positron emission tomography
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viewed the perioperative mortality, morbidity, and outcome
of pneumonectomies performed after neoadjuvant chemo-
therapy or chemoradiotherapy in patients with locally
advanced NSCLC.MATERIALS AND METHODS
A retrospective analysis on patients with locally advanced NSCLC
who were treated from 1998 to 2007 with neoadjuvant chemotherapy or
chemoradiotherapy followed by pneumonectomy at the Ruhrlandklinik,
Essen-Heidhausen, Germany, and the University Hospital Zurich, Zurich,
Switzerland, was performed. Data were collected from the clinical charts,
operating reports, and pathology reports, and survival data were retrieved
from the institutional lung cancer follow-up registry. Follow-up was com-
plete in all patients. Permission to perform such an outcome analysis was
included in the informed consents before surgery.
In the time period chosen, 827 patients with potentially resectable clin-
ical T4, N2, or N3 NSCLC underwent neoadjuvant therapy followed by sur-
gery. Pneumonectomies were performed in 176 patients; this cohort formed
the basis of our analysis. The median age at time of surgery was 56 years
(range, 33–74 years), and 122 of 176 patients (69%) were male. Neoadju-
vant chemotherapy consisted of 3 to 4 cycles of platin-based doublets. Pa-
tients treated with neoadjuvant chemoradiotherapy received 45 Gy (1.5 Gy,
bi-daily) to the primary tumor and mediastinal lymph nodes. In patients who
received radiotherapy in Essen, an additional cycle of platin-based doublets
was added. Treatment regimens were applied according to different treat-
ment protocols that changed over time in the 2 institutions.
Tumors were classified and staged according to the 1997 International
System for Staging of Lung Cancer.8 Staging and restaging were routinely
performed with computed tomography (CT) of the chest and upper abdo-
men, and mediastinoscopy or, more recently, endobronchial ultrasound-
guided fine-needle aspiration. Mediastinal lymph node involvement was
confirmed by histology or cytology. Additional staging tests, such as posi-
tron emission tomography integrated (PET) in CT, brain CT/magnetic res-
onance imaging, and bone scintigraphy, were used according to local
protocols and clinical signs and symptoms. T4 tumors in our series included
local invasion only. Patients with 2 lesions in 1 lobe or malignant pleural
effusion were excluded. Patients were selected for surgery when complete
resection was expected on the basis of the preoperative evaluation of the
CT or PET/CT scan and when the pulmonary reserve of the patient was suf-
ficient without relevant cardiac or other comorbidities. If necessary, physi-
ologic eligibility for pneumonectomy was assessed with 99mTc lung
perfusion scintigraphy to better predict postoperative lung function. Patients
with an objective response or at least stable disease after neoadjuvant ther-
apy were primarily, but not exclusively, selected for surgery.
Pneumonectomies were performed using similar techniques within both
centers. An anterolateral thoracotomy in the fourth or fifth intercostal space
was performed. Staplers were used for closing the pulmonary arteries, pul-
monary veins, and main bronchus in most cases. The right and left bronchial
stumps were regularly covered with a pericardial fat pad in Essen and irreg-The Journal of Thoracic and Carularly in Zurich with a pericardial fat pad, an intercostal muscle flap, or noth-
ing. In cases of local invasion, additional structures, such as pericardium
(intrapericardial resection), vena cava, aorta, trachea, and others, were re-
sected to get clear margins. A lymphadenectomy of the mediastinal lymph
nodes, performed according to the European Society of Thoracic Surgeons
guidelines, was an integral part of the procedure.9 One chest tube without
suction was placed in the chest and removed within 24 hours if no signifi-
cant bleeding was present. Patients were kept in the intermediate or inten-
sive care unit for 24 hours postoperatively or according to clinical needs
before discharged to the ward.
Few patients received further postoperative therapy. This included 3 pa-
tients with incomplete resection who received postoperative radiotherapy to
the local site and 4 patients with persisting N2 disease who received radio-
therapy to the mediastinum.
Statistical analysis was performed using patched SPSS 16.0 for Win-
dows software (SPSS Inc, Chicago, Ill). Univariate logistic regression
was used to assess the impact of relevant variables on the incidence of post-
operative complications. Age, type of induction therapy, and side and type
of pneumonectomy were used to assess the incidence of major postoperative
complications, and type of induction therapy, presence of tracheal sleeve re-
section, and side of pneumonectomy were used to assess the incidence of
bronchopleural fistula (BPF). Overall survival was estimated from the
date of surgery using the Kaplan–Meier survival analysis method. The im-
pact on survival of 14 variables—age, gender, preinduction clinical stage,
preinduction clinical T, N, M status, type of induction therapy, tumor histol-
ogy, type of operation, postinduction pathologic stage, postinduction path-
ologic T, N, M status, and R-resection status—were assessed by Cox
regression for continuous and log-rank test or Breslow test when necessary
for discrete variables. Variables with statistic significance were further an-
alyzed in a multiple Cox regression model (forward/backward).
RESULTS
From 1998 to 2007, 176 patients underwent a pneumonec-
tomy after neoadjuvant chemotherapy or chemoradiother-
apy for locally advanced NSCLC, representing 21% of the
resections treated with such a combined approach.
Neoadjuvant chemotherapy alone was administered in 35
patients (20%), and neoadjuvant chemoradiotherapy was
administered in 141 patients (80%). At diagnosis, 8 patients
were classified as stage IIB, 72 patients were classified as
stage IIIA, 94 patients were classified as stage IIIB, and 2 pa-
tients were classified as stage IV with solitary brain metasta-
sis (Table 1). N2/N3 was pathologically proven by cytology
or histology. Complete response was recorded in 36 patients
(21%), all having received chemoradiotherapy (Figure 1).
Of 176 pneumonectomies, 86 (49%) were right-sided
and 138 (78%) were extended because of additional resec-
tions. This is summarized in Table 2. R0 resection wasdiovascular Surgery c Volume 139, Number 6 1425
FIGURE 1. Response to induction therapy.
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had R1 or R2 resection.
Histology was squamous cell carcinoma in 101 patients
(57%), adenocarcinoma in 46 patients (26%), large cell car-
cinoma in 17 patients (10%), and not otherwise specified in
12 patients (7%).
Postoperative 90-day mortality was 3%. Three patients
died of pulmonary embolism, 2 patients died of respiratory
failure (pneumonia/acute respiratory distress syndrome
[ARDS]), and 1 patient died of cardiac failure. Within 90
postoperative days, 23 major complications occurred in
22 patients (13%): Six patients had pneumonia/ARDS,
5 patients had BPF, 5 patients had empyema without BPF,
3 patients had pulmonary embolism, 2 patients had hemo-
thorax necessitating reoperation, 1 patient had heart failure,
and 1 patient had gastric herniation caused by technical fail-
ure of the diaphragmatic repair.
Univariate logistic regression showed that patients with
induction chemoradiotherapy had fewer major postoperative
complications than patients with chemotherapy alone
(P¼ .024, odds ratio¼ 0.344). Univariate logistic regressionTABLE 2. Type of resection associated with extended
pneumonectomies after induction treatment
Type of resection n %
Pericardium 112 81
Left atrium 28 20
Parietal pleura 24 17
Trachea/carina 9 7
Chest wall 8 6
Superior vena cava 8 6
Pulmonary artery truncus 8 6
Diaphragm 7 5
Aorta 4 3
Esophageal wall 3 2
1426 The Journal of Thoracic and Cardiovascular Surfor variables such as age (P¼ .171), side of pneumonectomy
(P¼ .155), and type of operation (P¼ .081) failed to show an
influence on major morbidity. BPF occurred in 3 covered
stumps (2 right and 1 left pneumonectomies) and 2 uncov-
ered stumps (all right pneumonectomies). Univariate logistic
regression did not show any statistically significant impact of
the type of induction treatment (P ¼ .272), the presence of
tracheal sleeve resection (P ¼ .999), or the side of pneumo-
nectomy (P ¼ .193) on BPF occurrence.
The median survival of all patients was 23 months; 3- and
5-year survivals were 43% and 38%, respectively (Figure 2).
Univariate and multiple Cox regression models identified 6
and 3 statistically significant predictors for survival,FIGURE 2. Overall survival after induction therapy and pneumonectomy
for NSCLC.
gery c June 2010
TABLE 3. Identification of survival predictors in univariate and
multiple Cox regression analyses
Covariates b P value HR 95% CI
Univariate analysis
Age .361*
Gender .361y
cStage .592y
cT status .793y
cN status 0.3 .007* 1.4 1.1–1.8
cM status .886y
Type of neoadjuvant treatment .062y
Histology
SC vs AD 0.7 .002* 2.0 1.3–3.1
SC vs LC 1.1 <.001* 3.1 1.7–5.7
SC vs other .101*
Type of operation .558y
ypStage 0.1 <.001* 1.0 1.0–1.1
ypT status .071y
ypN status 0.3 .003* 1.4 1.1–1.7
ypM status 1.2 <.001* 3.2 1.8–5.7
R-resection 0.8 .008* 2.3 1.2–4.4
Multiple Cox analysis
Histology
SC vs AD 0.5 .027* 1.7 1.1–2.6
SC vs LC 1.1 .001* 2.9 1.5–5.4
SC vs other 0.7 .097* 1.9 0.9–4.0
R-resection 0.9 .012* 2.3 1.2–4.6
cN status 0.2 .073* 1.2 1.0–1.6
ypM status 0.8 .032* 2.1 1.1–4.3
HR, Hazard ratio; CI, confidence interval; SC, squamous cell carcinoma; AD, adeno-
carcinoma; LC, large cell carcinoma. b¼ coefficient. *P values were derived from the
Cox regression analysis. yP values were derived from the log-rank or Breslow tests
when necessary.
FIGURE 3. Survivals for locally advanced preinduction clinical stages
IIIA and IIIB NSCLC.
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respective 95% confidence intervals are summarized in
Table 3.
There was no difference in survival between patients pre-
senting with stage IIIA and patients presenting with stage
IIIB (P ¼ .669 (Figure 3). Survival for stages IIIA and
IIIB was further analyzed according to patients’ T and N sta-
tus (Figure 4). No statistical significance in survival among
stages IIIA (T1-3N2), IIIB (T4N0-2), IIIB (T1-3N3), and
IIIB (T4N3) was demonstrated (P ¼ .660).
Figure 5 shows survival according to pathologic stage at
surgery after neoadjuvant therapy. The best survival was
found for patients with complete response after neoadjuvant
therapy, who had a 5-year survival of 56%. Patients down-
graded to stages I and II had a 5-year survival of 35% and
34%, respectively. Patients with persisting stage III disease
had a 5-year survival of 31%, whereas all patients with stage
IV disease documented at surgery died within 3 years.FIGURE 4. Survival for preinduction clinical stages IIIA and IIIB, accord-
ing to their T and N status.DISCUSSION
The treatment of patients with locally advanced NSCLC
remains a challenge and is discussed controversially. In gen-The Journal of Thoracic and Careral, patients benefit from surgery, when a radical resection
can be achieved with a low morbidity and mortality. Al-
though there is consensus about the indication for a multimo-
dality approach in most patients with locally advanced
disease, there is no clear agreement about which local ther-
apy should be applied in a given situation.
Recent studies suggested missing benefits, as well as un-
acceptable high morbidity and mortality, for patients with
locally advanced NSCLC treated by resection after neoadju-
vant therapy. The European Organisation for Research and
Treatment of Cancer trial published by Van Meerbeck and
colleagues10 reported similar survival after surgery or radio-
therapy after neoadjuvant chemotherapy in 154 patients with
stage IIIA N2 disease judged to be primarily unresectable.diovascular Surgery c Volume 139, Number 6 1427
FIGURE 5. Stage-related survival after induction therapy and pneumonec-
tomy for NSCLC.
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than 50% after neoadjuvant therapy, and therefore the lack
of a survival advantage in the surgical arm should not be in-
terpreted as a surprise. Nevertheless, patients with complete
resection reached a 27% 5-year survival compared with an
overall 5-year survival of 15.7% in the surgery arm and
14% in the radiation arm. This confirms once again that
only a complete resection has a positive impact on survival
and that incomplete resection is comparable to radiotherapy.
The heterogeneity of stage III NSCLC and the variability
of definitions of what constitutes resectable disease among
different surgeons make it difficult to state general rules as
to the applicability of surgery. The clinical extremes toward
resectability, a diseased single nodal station not adherent to
a vital structure versus multilevel bulky and confluent lymph
nodes, are easily recognized. But there is a grey zone in be-
tween where imaging techniques and definitions count, but
also clinical experience. This is specifically a dilemma be-
cause patient selection is of paramount importance. The uni-
variate (P¼ .037, HR¼ 1.4), but not the multiple (P¼ .073),
analysis confirmed the importance of clinical N-status at pre-
sentation on survival. Furthermore, our study reconfirms that
good responders to neoadjuvant chemotherapy or chemora-
diotherapy have a better survival. Pathologic stage at surgery
(P<.001, HR¼ 1.0), N status (P¼ .003, HR ¼ 1.4), and M
status (P< .001, HR ¼ 3.2) were significant predictors of
survival in a univariate analysis; M status (P ¼ .032,
HR ¼ 2.1) was confirmed in the multiple analysis.
Differences in clinical staging procedures and inclusion
criteria for neoadjuvant therapy, as well as the presence of
small patient cohort studies, render the comparison of long-
term survival among studies difficult. Five-year survival after
neoadjuvant therapy for stage III disease was reported be-
tween 30% and 40%.11-13 One small recent study with 351428 The Journal of Thoracic and Cardiovascular Surpneumonectomies after neoadjuvant treatment in patients
with clinical preoperative stage IIIA ‘‘minimal N2
disease’’ (with a maximum of 2 positive mediastinal lymph
node stations and no extranodal growth) and T4N0M0
disease reported an encouraging 5-year survival of 46%.4
In our experience with a high proportion of stage IIIB dis-
ease, the 5-year survival was 38%. This excellent survival
could be explained by various components, such as a high
complete resection rate with a low perioperative mortality,
a high remission rate after chemoradiotherapy (21%), and
an accurate selection of patients for surgery via an efficient
staging/restaging process with PET/CT, mediastinoscopy,
or endobronchial ultrasound-guided fine-needle aspiration.
Not surprisingly, squamous cell carcinoma appeared in
the univariate and multiple analyses as a statistically signif-
icant favorable histology regarding survival compared with
adenocarcinoma (P ¼ .002, HR ¼ 2.0 and P ¼ .027,
HR ¼ 1.7) and large cell carcinoma (P< .001, HR ¼ 3.1
and P ¼ .001, HR ¼ 2.9).
As shown in many studies, R0 resections had a favorable
impact on survival, compared with incomplete resections in
univariate analysis (P ¼ .008, HR ¼ 2.3) and multiple
(P ¼ .012, HR ¼ 2.3) analyses.
Albain and colleagues14 recently reported the results of
a phase III controlled randomized trial of radiotherapy plus che-
motherapy with or without surgical resection in 396 patients
with stage IIIA N2 NSCLC. No survival difference was shown
between the surgical and nonsurgical arms. A closer look at this
study, however, shows that the mortality rate for patients after
pneumonectomy was as high as 26%. Patients who received
a lobectomy after chemoradiotherapy and without such ex-
ceedingly high perioperative mortality had a clear survival ben-
efit compared with a matched control group.
The high mortality rate of pneumonectomies after neoad-
juvant therapy reported in this randomized study and the
high rate of incomplete resection described in the other ran-
domized study from Van Meerbeck and colleagues10 dif-
fered markedly from the perception we had from our own
experience and prompted us to perform this retrospective
analysis of patients undergoing pneumonectomy after neo-
adjuvant chemotherapy or chemoradiotherapy.
Within pulmonary resections, pneumonectomy has been
associated with the highest morbidity and mortality of all
elective thoracic surgical procedures. Without neoadjuvant
treatment, mortality after pneumonectomy has been reported
between 1.6% and 13.4%.15,16
Even recent reviews note that neoadjuvant treatment,
especially chemoradiotherapy, increases the risk of postoper-
ative complications and deaths.17 Preoperative high-dose ra-
diotherapy (>45 Gy) proved to be a significant risk factor
for postoperative complications in several studies.6,7
In our study, neoadjuvant chemotherapy and chemoradio-
therapy were given in 35 and 141 patients, respectively, and
followed by mostly extended pneumonectomies withgery c June 2010
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Sa postoperative mortality rate of 3%. Some smaller studies
showed comparable results for pneumonectomy after neoad-
juvant chemotherapy, with death rates reaching less than
7.5%.11,18 The use of radiotherapy (45 Gy) as component
of the neoadjuvant treatment19 did not increase the rate of
complications or mortality in our study. This favorable out-
come may be the result of a careful patient selection for
pneumonectomy taking into account performance status,
pulmonary and cardiovascular function tests, and the exten-
sive surgical and anesthesiologic experience available in the
centers participating in this analysis. Although most of the
pneumonectomies were extended resections, major morbid-
ity occurred in only 13% of patients. The comparison of
overall morbidity rates between studies is difficult because
of varying definitions of postoperative complications. Com-
plication rates in our study were 3.4% for pneumonia/
ARDS, 2.8% for post-pneumonectomy empyema without
bronchus stump insufficiency, and 2.8% for bronchus stump
insufficiency. Our morbidity rates are among the lowest
when compared with reports of the literature. For example,
postoperative ARDS has been reported between 1.8% and
46%, with higher rates observed in particular after neoadju-
vant chemoradiotherapy.3,7,11,20,21 The rate of pneumonia
varies in the literature from 3% to 19%.11,20-23 The rate of
empyema reported after neoadjuvant therapy ranged from
1.3% to 7.4%.3,20,21 Bronchus stump insufficiency after
neoadjuvant therapy and pneumonectomy was reported
between 0% and 14%, including a higher risk after right-
sided procedures.3,7,11,18 The increased frequency of
bronchus stump insufficiency on the right side is well
known and explained by the fact that the right stump is
more exposed in the pleural space and less naturally
buttressed by mediastinal structures. Bronchial stump-
covering techniques have been proven as highly effective
procedures to prevent BPF.24 In our institutions, bronchial
stumps after neoadjuvant therapy are covered whenever pos-
sible with pre-pericardial fat pad or intercostal muscle. Bron-
chus stump insufficiency occurred in 3 covered stumps
(1 left and 2 right pneumonectomies) and 2 uncovered
stumps (all right pneumonectomies). Univariate logistic re-
gression failed to show an influence of the type of induction
treatment (P ¼ .272), the presence of tracheal sleeve resec-
tion (P¼ .999), or the side of pneumonectomy (P¼ .193) on
BPF occurrence (data not shown).
CONCLUSIONS
The results of our retrospective analysis demonstrate that
pneumonectomy after neoadjuvant chemotherapy or chemo-
radiotherapy with 45 Gy for locally advanced stage IIIA and
IIIB NSCLC can be performed safely with a mortality rate of
3%, a 90-day major morbidity of 13%, and an encouraging
overall 5-year survival of 38%. The importance of sufficient
hospital volume on the surgical outcome of such complex
procedures has also been highlighted.25 These results chal-The Journal of Thoracic and Carlenge any surgical nihilism for patients with locally advanced
NSCLC and emphasizes that surgery, when performed in ex-
perienced centers, continues to have an important role within
the multimodality therapy of these patients.References
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Dr Robert Cerfolio (Birmingham, Ala). These survival results
are going to be unbelievable to many, especially when you have 27
patients with N3 disease and many with T4 disease. Therefore, can
you tell us how you have such great survival in patients with N3,
how you reassess N3, and are these nodes that are contiguous N3
as opposed to distant N3? As we all know, a Pancoast gives an
N3 with a supraclavicular node, but that is really probably an N1.
What kind of N3 nodes are these?
Dr Weder. Thank you for asking this question because this ex-
plains why we included N3 disease. As you know, the TNM staging
system has its limitations, and N3 disease is not always N3 disease,
N2 disease is not N2 disease. As you pointed out, in a centrally lo-
cated tumor and a positive node adjacent to the tumor it is N2 or N3.
By its biological behavior, it is probably most likely an N1 disease.
You mentioned the Pancoast situation, where the supraclavicular
lymph nodes are also not considered N3 but N1 disease.
Then there is another group of N3 disease that we have included,
and this started when we had PET/CT scan available. We found iso-
lated lymph nodes in the contralateral site at 1 station, and we asked
ourselves the question, why do we have to exclude them? If they
would be 5 mm closer to the ipsilateral site, it would be an N2
and we would do induction therapy. So we performed induction
therapy followed by surgery in a couple of these patients, and we
found long-term survival and even cure, and thereafter we did
a phase II multicenter study including these patients, and this paper
is currently under review for publication.
Dr Cerfolio. You heard yesterday in our breakout session how
the medical oncologists and radiation oncologists want us to use cu-
rative doses of chemoradiotherapy beforehand, and I personally
agree with that and made that cognitive leap almost 10 years ago,
in 2000, and we have written about how it is safe to do a thoracot-
omy and pulmonary resection after 66 or even 70 Gy. You use 45
Gy. Are you going to make that cognitive leap, and do you think
you can do a pneumonectomy after 60 or 66 cGy? Don’t you think
this offers maximal medical therapy in case surgery is not offered
and thus avoids gaps and delays in the delivered amount of radia-
tion dose before surgery?
Dr Weder. The more radiotherapy you apply, the higher risk of
mortality and morbidity. This is clearly documented in the litera-1430 The Journal of Thoracic and Cardiovascular Surture. We have to balance this. How much risk do we want to
take? This is a question that should be addressed by a multicenter
study. We should compare 45 with 60 cGy and then go thereafter
for surgery, because if you achieve good downstaging with 45
cGy and have resectability, then it favors this approach, because
you have definitely less morbidity and mortality. So I favor a mul-
ticenter randomized study.
Dr Cerfolio. It sounds like you are not willing to make that leap,
but we will talk about it later. My third and final question is the re-
assessment of N2 nodes. Most of us would say if those N2 nodes
are still positive, we certainly wouldn’t do a pneumonectomy,
maybe a lobectomy in a young patient, but not a pneumonectomy.
So tell me how you reassess the mediastinum (repeat endobronchial
ultrasound, repeat endobronchial ultrasound-guided fine-needle as-
piration, repeat mediastinoscopy), and when do you not believe the
results based on the PET’s percentage change in the maximum stan-
dardized uptake value and then do a more invasive biopsy, such as
video-assisted thoracic surgery in the opposite chest, where the le-
sions are located?
Dr Weder. The reassessment is sometimes easy and sometimes
difficult. I think it is easy for us when there is a good response to
the treatment. We usually do not reassess the mediastinum in patients
with a good response. They go for surgery directly. Those who are
progressive are not candidates. But then there are the ones in between,
and in our study they were reassessed by mediastinoscopy if this
influenced the decision for resection, because at that time EBUS
was not available yet, only maybe the last 1 or 2 years of the study.
Dr Mark Krasna (Towson, Md). Again, I’d like to focus on the
group that received chemotherapy with radiation therapy, and I
think that subgroup is of greatest interest to us. Tom Treasure’s re-
cent article in the European Journal emphasized that we don’t al-
ways have to do a prospective randomized trial to answer an
intuitively correct question. Your institution now is the sixth series
in the thoracic literature, which is large enough for us to analyze re-
sults of pneumonectomy after chemoradiotherapy, and these re-
sults, like the ones from Rush, Alabama, our own in Baltimore,
Ben Daley’s group in Boston, and one from Poland last year, all
show that you can do this treatment approach with less than 26%
mortality and no difference between right and left.
My question to you is very specific regarding a patient who has
N2 disease. If you were to give that patient chemotherapy and radi-
ation therapy up front, as you see that your results of pathologic com-
plete response are better than the rest, why are you persisting in only
giving patients chemotherapy followed by surgery? Why not at least
give all the patients chemotherapy with radiation at 45 cGy or, as
Cerf says, chemotherapy with full-dose radiation at 60 cGy?
Dr Weder. I think scientifically the answer is not clear yet, and
we are currently performing a study randomizing them in chemo-
therapy versus chemoradiotherapy.
Dr Krasna. There are no data in the literature to show a pathologic
response rate anything greater than 4% with chemotherapy alone.
Dr Weder. Complete pathologic response is seen in 8% to 13%
after chemotherapy alone. However, we used chemoradiotherapy
in 80% of the patients, which may explain the higher response rate.gery c June 2010
